WO2001035940A3 - Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride - Google Patents

Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride Download PDF

Info

Publication number
WO2001035940A3
WO2001035940A3 PCT/GB2000/004363 GB0004363W WO0135940A3 WO 2001035940 A3 WO2001035940 A3 WO 2001035940A3 GB 0004363 W GB0004363 W GB 0004363W WO 0135940 A3 WO0135940 A3 WO 0135940A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolidinedione
metformin hydrochloride
pharmaceutical composition
composition
metformin
Prior art date
Application number
PCT/GB2000/004363
Other languages
French (fr)
Other versions
WO2001035940A2 (en
Inventor
Karen Lewis
Nicola Jayne Lillott
Donald Colin Mackenzie
Original Assignee
Smithkline Beecham Plc
Karen Lewis
Nicola Jayne Lillott
Donald Colin Mackenzie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927121.5A external-priority patent/GB9927121D0/en
Priority claimed from GB0013238A external-priority patent/GB0013238D0/en
Application filed by Smithkline Beecham Plc, Karen Lewis, Nicola Jayne Lillott, Donald Colin Mackenzie filed Critical Smithkline Beecham Plc
Priority to EP00976151A priority Critical patent/EP1231917A2/en
Priority to AU14035/01A priority patent/AU1403501A/en
Priority to JP2001537933A priority patent/JP2003514011A/en
Publication of WO2001035940A2 publication Critical patent/WO2001035940A2/en
Publication of WO2001035940A3 publication Critical patent/WO2001035940A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising a thiazolidinedione metformin hydrochloride, and a pharmaceutically acceptable carrier, wherein the thiazolidinedione is formulated upon the surface of the metformin hydrochloride and the use of such composition in medicine.
PCT/GB2000/004363 1999-11-16 2000-11-16 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride WO2001035940A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00976151A EP1231917A2 (en) 1999-11-16 2000-11-16 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
AU14035/01A AU1403501A (en) 1999-11-16 2000-11-16 Novel composition and use
JP2001537933A JP2003514011A (en) 1999-11-16 2000-11-16 Pharmaceutical composition comprising thiazolidinedione-metformin hydrochloride

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9927121.5A GB9927121D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GB9927121.5 1999-11-16
GB0013238A GB0013238D0 (en) 2000-05-31 2000-05-31 Novel composition and use
GB0013238.1 2000-05-31

Publications (2)

Publication Number Publication Date
WO2001035940A2 WO2001035940A2 (en) 2001-05-25
WO2001035940A3 true WO2001035940A3 (en) 2002-03-21

Family

ID=26244395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004363 WO2001035940A2 (en) 1999-11-16 2000-11-16 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride

Country Status (4)

Country Link
EP (1) EP1231917A2 (en)
JP (1) JP2003514011A (en)
AU (1) AU1403501A (en)
WO (1) WO2001035940A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU5745601A (en) * 2000-05-01 2001-11-12 Aeropharm Technology Inc A core formulation
AU2001273310B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. A core formulation
MXPA04000181A (en) * 2001-07-10 2004-11-22 Kos Life Sciences Inc Core formulation comprising troglitazone and a biguanide.
US20060286168A1 (en) * 2002-07-11 2006-12-21 Masahiko Koike Process for producing coated preparation
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (en) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 Pharmaceutical tablet
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1588708A4 (en) * 2003-01-29 2006-03-01 Takeda Pharmaceutical Process for producing coated preparation
CN1761465B (en) * 2003-01-29 2010-10-13 武田药品工业株式会社 Method for manufacturing coated formulation
JP4567340B2 (en) * 2003-01-29 2010-10-20 武田薬品工業株式会社 Method for producing coated preparation
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2010136847A1 (en) * 2009-05-26 2010-12-02 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Coated metformin with pioglitazone solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
WO1999003477A1 (en) * 1997-07-18 1999-01-28 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
WO1999003477A1 (en) * 1997-07-18 1999-01-28 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides

Also Published As

Publication number Publication date
AU1403501A (en) 2001-05-30
WO2001035940A2 (en) 2001-05-25
JP2003514011A (en) 2003-04-15
EP1231917A2 (en) 2002-08-21

Similar Documents

Publication Publication Date Title
WO2001035941A3 (en) Novel composition based on a thiazolidinedione and metformin and use
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
CA2420694A1 (en) Guanidinobenzamides as mc4-r agonists
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
WO2000061115A3 (en) Pharmaceutical formulation comprising amoxycillin
IL185118A0 (en) 5-membered heterocycle derivatives,production thereof and use thereof as medicaments
HK1042897A1 (en) Thiazole and oxazole derivatives and their pharmaceutical use.
WO2001008688A3 (en) Beta-carboline drug products
AU7802700A (en) Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
WO2002060422A3 (en) Treatment of diabetes mellitus using vardenafil
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
MY128896A (en) Pharmaceutical combinations
IL143987A (en) Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
CA2292629A1 (en) Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione
WO2001082868A3 (en) A medicinal aerosol formulation
AU2002308889A1 (en) Novel heterocyclic compound and medicinal use thereof
AU5745601A (en) A core formulation
AUPQ462299A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU7684000A (en) Interferon complex and medicinal use thereof
EP0974353A3 (en) The use of homocysteine derivatives for the preparation of medicaments inhibiting bacterial adhesiveness
AU2002347402A1 (en) Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative
AU2002237251A1 (en) A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000976151

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 537933

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10130224

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000976151

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000976151

Country of ref document: EP